Literature DB >> 21839013

Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination.

Nicoletta Masera1, Luisa Tavecchia, Daniela Valentina Longoni, Oscar Maglia, Andrea Biondi, Giuseppe Masera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21839013      PMCID： PMC3200417          DOI： 10.2450/2011.0098-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  19 in total

1.  Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience.

Authors:  H P Pati; V P Choudhry
Journal:  Eur J Haematol       Date:  1999-10       Impact factor: 2.997

2.  Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial.

Authors:  A V Hoffbrand; A N Bartlett; P A Veys; N T O'Connor; G J Kontoghiorghes
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

Review 3.  Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.

Authors:  Charalampos Pontikoglou; Helen A Papadaki
Journal:  Hemoglobin       Date:  2010-06       Impact factor: 0.849

4.  The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.

Authors:  Adriana Ceci; Paola Baiardi; Mariagrazia Felisi; Maria Domenica Cappellini; Vittorio Carnelli; Vincenzo De Sanctis; Renzo Galanello; Aurelio Maggio; Giuseppe Masera; Antonio Piga; Francesco Schettini; Ippazio Stefàno; Fernando Tricta
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

5.  Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.

Authors:  Antoni Piga; Carmen Gaglioti; Eugenia Fogliacco; Fernando Tricta
Journal:  Haematologica       Date:  2003-05       Impact factor: 9.941

6.  Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.

Authors:  F N al-Refaie; C Hershko; A V Hoffbrand; M Kosaryan; N F Olivieri; P Tondury; B Wonke
Journal:  Br J Haematol       Date:  1995-09       Impact factor: 6.998

7.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Authors:  Alan R Cohen; Renzo Galanello; Antonio Piga; Vincenzo De Sanctis; Fernando Tricta
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

8.  Deferiprone-associated myelotoxicity.

Authors:  F N al-Refaie; B Wonke; A V Hoffbrand
Journal:  Eur J Haematol       Date:  1994-11       Impact factor: 2.997

Review 9.  Long-term therapy with deferiprone.

Authors:  N F Olivieri
Journal:  Acta Haematol       Date:  1996       Impact factor: 2.195

10.  Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one.

Authors:  F N al-Refaie; P A Veys; S Wilkes; B Wonke; A V Hoffbrand
Journal:  Acta Haematol       Date:  1993       Impact factor: 2.195
View more
  3 in total

1.  Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.

Authors:  Saumya S Jamuar; Angeline H M Lai
Journal:  Ther Adv Hematol       Date:  2012-10

2.  Agranulocytosis with deferiprone treatment of superficial siderosis.

Authors:  Nikhil Huprikar; Marisa Gossweiler; Maureen Callaghan; Paul Bunge
Journal:  BMJ Case Rep       Date:  2013-08-07

3.  Deferiprone-induced agranulocytosis: 20 years of clinical observations.

Authors:  Fernando Tricta; Jack Uetrecht; Renzo Galanello; John Connelly; Anna Rozova; Michael Spino; Jan Palmblad
Journal:  Am J Hematol       Date:  2016-08-04       Impact factor: 10.047
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.